TABLE 3.
Results of a secondary meta‐analysis.
| MADRS (SMD [95% CI]) | ||||
| ARI3 | −0.099 (−0.285, 0.086) | −0.132 (−0.389, 0.125) | −0.173 (−0.430, 0.085) | −0.376 (−0.562, −0.190) |
| ARI (flexible) | −0.033 (−0.258, 0.193) | −0.074 (−0.299, 0.152) | −0.277 (−0.416, −0.138) | |
| BRE1 | −0.041 (−0.217, 0.136) | −0.244 (−0.422, −0.066) | ||
| BRE2 | −0.203 (−0.381, −0.026) | |||
| PLA | ||||
| Nonresponse rate (OR [95% CI]) | ||||
| ARI3 | 0.897 (0.614, 1.311) | 0.774 (0.434, 1.382) | 0.737 (0.412, 1.319) | 0.531 (0.360, 0.783) |
| ARI (flexible) | 0.863 (0.511, 1.457) | 0.822 (0.485, 1.391) | 0.592 (0.439, 0.798) | |
| BRE1 | 0.952 (0.633, 1.432) | 0.686 (0.446, 1.054) | ||
| BRE2 | 0.720 (0.467, 1.110) | |||
| PLA | ||||
| Nonremission rate (OR [95% CI]) | ||||
| ARI3 | 0.902 (0.603, 1.348) | 0.743 (0.390, 1.416) | 0.733 (0.384, 1.400) | 0.541 (0.356, 0.823) |
| ARI (flexible) | 0.824 (0.458, 1.484) | 0.813 (0.451, 1.467) | 0.600 (0.434, 0.830) | |
| BRE1 | 0.987 (0.621, 1.568) | 0.729 (0.446, 1.190) | ||
| BRE2 | 0.738 (0.451, 1.209) | |||
| PLA | ||||
| CGI‐S (SMD [95% CI]) | ||||
| ARI3 | −0.072 (−0.257, 0.113) | −0.086 (−0.342, 0.170) | 0.042 (−0.215, 0.299) | −0.213 (−0.399, −0.028) |
| ARI (flexible) | −0.014 (−0.238, 0.212) | 0.114 (−0.112, 0.340) | −0.141 (−0.280, −0.002) | |
| BRE1 | 0.128 (−0.049, 0.304) | −0.128 (−0.305, 0.050) | ||
| BRE2 | −0.255 (−0.433, −0.077) | |||
| PLA | ||||
| Social function (SMD [95% CI]) | ||||
| ARI3 | 0.039 (−0.160, 0.237) | −0.126 (−0.404, 0.151) | −0.132 (−0.410, 0.146) | −0.396 (−0.596, −0.197) |
| ARI (flexible) | −0.165 (−0.410, 0.080) | −0.171 (−0.416, 0.075) | −0.435 (−0.586, −0.285) | |
| BRE1 | −0.006 (−0.198, 0.187) | −0.270 (−0.464, −0.076) | ||
| BRE2 | −0.264 (−0.459, −0.070) | |||
| PLA | ||||
| All‐cause discontinuation (OR [95% CI]) | ||||
| ARI3 | 1.170 (0.464, 2.953) | 1.201 (0.287, 5.030) | 0.491 (0.125, 1.932) | 1.170 (0.453, 3.024) |
| ARI (flexible) | 1.026 (0.283, 3.718) | 0.419 (0.124, 1.417) | 1.000 (0.491, 2.038) | |
| BRE1 | 0.409 (0.152, 1.097) | 0.975 (0.333, 2.850) | ||
| BRE2 | 2.384 (0.888, 6.397) | |||
| PLA | ||||
| Discontinuation because of adverse events (OR [95% CI]) | ||||
| ARI3 | 1.222 (0.450, 3.316) | 3.217 (0.415, 24.923) | 0.495 (0.085, 2.900) | 3.139 (0.887, 11.115) |
| ARI (flexible) | 2.634 (0.386, 17.997) | 0.405 (0.080, 2.049) | 2.570 (0.900, 7.336) | |
| BRE1 | 0.154 (0.045, 0.529) | 0.976 (0.195, 4.882) | ||
| BRE2 | 6.342 (1.843, 21.819) | |||
| PLA | ||||
| At least one adverse event (OR [95% CI]) | ||||
| ARI3 | 0.828 (0.415, 1.653) | 1.304 (0.495, 3.437) | 0.748 (0.282, 1.988) | 1.478 (0.749, 2.916) |
| ARI (flexible) | 1.575 (0.667, 3.718) | 0.904 (0.379, 2.153) | 1.784 (1.071, 2.973) | |
| BRE1 | 0.574 (0.284, 1.158) | 1.133 (0.568, 2.261) | ||
| BRE2 | 1.975 (0.979, 3.985) | |||
| PLA | ||||
| Akathisia (OR [95% CI]) | ||||
| ARI3 | 0.365 (0.088, 1.518) | 0.542 (0.049, 6.045) | 0.107 (0.010, 1.150) | 2.778 (0.621, 12.421) |
| ARI (flexible) | 1.484 (0.162, 13.598) | 0.294 (0.033, 2.578) | 7.608 (2.399, 24.126) | |
| BRE1 | 0.198 (0.043, 0.921) | 5.127 (0.774, 33.978) | ||
| BRE2 | 25.914 (4.113, 163.285) | |||
| PLA | ||||
| Tremor (OR [95% CI]) | ||||
| ARI3 | 0.911 (0.156, 5.314) | 1.070 (0.075, 15.269) | 1.427 (0.099, 20.666) | 1.911 (0.303, 12.032) |
| ARI (flexible) | 1.175 (0.110, 12.505) | 1.566 (0.145, 16.956) | 2.097 (0.526, 8.368) | |
| BRE1 | 1.333 (0.201, 8.825) | 1.785 (0.262, 12.153) | ||
| BRE2 | 1.339 (0.193, 9.306) | |||
| PLA | ||||
| Weight gain (OR [95% CI]) | ||||
| ARI3 | 0.665 (0.269, 1.646) | 1.785 (0.352, 9.060) | 1.655 (0.327, 8.370) | 5.493 (1.462, 20.643) |
| ARI (flexible) | 2.683 (0.653, 11.030) | 2.487 (0.607, 10.185) | 8.257 (2.877, 23.705) | |
| BRE1 | 0.927 (0.474, 1.812) | 3.077 (1.200, 7.890) | ||
| BRE2 | 3.320 (1.303, 8.463) | |||
| PLA | ||||
Note: Drugs are reported alphabetically. Data are presented as odds ratios or standardized mean differences (95% confidence intervals) in the column‐defining treatment compared with the row‐defining treatment. Odds ratios <1 favor the row‐defining treatment. Standardized mean differences <0 favor the row‐defining treatment.
The boldface result indicates statistical significance.
Abbreviations: 95% CI, 95% confidence interval; ARI, aripiprazole; BRE, brexpiprazole; CGI‐S, Clinical Global Impression of illness Severity; MADRS, Montgomery Åsberg Depression Rating Scale; OR, odds ratio; PLA, placebo; SMD, standardized mean difference.